Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

RCUSRCUS
Showing 8 of 30 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in Arcus Biosciences, Inc.

CITADEL ADVISORS LLC holds 3.1M shares of RCUS (Arcus Biosciences, Inc.), worth $96.7M as of 2026-Q2. The position was increased (+135.7% shares). RCUS represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$96.7M

Current Shares

3.1M

Total Value Change

+$91.8M

Total Shares Change

+2.8M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3.1M
+135.7%
$96.7M0.0%$30.83
48
2026-Q1
Increased
1.3M
+1170.2%
$28.7M0.0%$22.43
46
2025-Q4
Decreased
104,701
-64.5%
$2.5M0.0%$23.23
0
2025-Q3
Decreased
295,054
-51.7%
$4M0.0%$13.32
0
2025-Q2
Increased
611,195
+62.1%
$5M0.0%$7.95
39
2025-Q1
Increased
377,098
+4.6%
$3M0.0%$8.17
28
2024-Q4
Increased
360,594
+13.4%
$5.4M0.0%$14.91
31
2024-Q3
Decreased
317,871
-32.0%
$4.9M0.0%$15.41
0

Other major holders of RCUS: BlackRock, Inc., BNP PARIBAS FINANCIAL MARKETS, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used